Needham & Company analyst Michael Matson lowered the price target on Medtronic, Inc. (NYSE: MDT) to $124.00 (from $128.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Medtronic, Inc. (MDT) PT Lowered to $122 at Evercore ISIFebruary 22, 2022 10:43 AM Medtronic to provide underserved communities with artificial intelligence (AI)-assisted colonoscopy technology through Health Equity Assistance Program for colon cancer screeningFebruary 22, 2022 10:30 AM Medtronic sees rebound in elective procedures as Omicron surge wanesFebruary 22, 2022 6:52 AM Form 8-K Medtronic plc For: Feb 22February 22, 2022 6:48 AM Medtronic (MDT) Reports In-Line Q3 EPS; Guides Q4 In-LineFebruary 22, 2022 6:46 AM Medtronic reports third quarter fiscal 2022 financial resultsFebruary 22, 2022 6:45 AM Medtronic (MDT) receives FDA expanded approval for cardiac cryoablation catheters for pediatric treatment of a common heart rhythm conditionFebruary 18, 2022 11:51 AM Medtronic receives FDA expanded approval for cardiac cryoablation catheters for pediatric treatment of a common heart rhythm conditionFebruary 18, 2022 11:50 AM